In the BioHarmony Drug Report Database

"Preview" Icon

Abaloparatide

Tymlos (abaloparatide) is a protein pharmaceutical. Abaloparatide was first approved as Tymlos on 2017-04-28. It is used to treat postmenopausal osteoporosis in the USA. The pharmaceutical is active against parathyroid hormone/parathyroid hormone-related peptide receptor. Tymlos’s patents are valid until 2038-04-30 (FDA).

 

Trade Name

 

Tymlos
 

Common Name

 

abaloparatide
 

ChEMBL ID

 

CHEMBL3301581
 

Indication

 

postmenopausal osteoporosis
 

Drug Class

 

Peptides: parathyroid hormone related peptide

Image (chem structure or protein)

Abaloparatide structure rendering